In this video, Gary Lemack, MD, offers a brief overview of overactive bladder treatments in development and explains their significance for providers and patients.
Gary Lemack, MD, of UT Southwestern Medical Center in Dallas, co-authored an article in the April 2020 issue of Urology Times® regarding how the development of new pharmacological and device-based treatments could change the management of overactive bladder. In this interview, Dr. Lemack offers a brief overview of treatments in development and explains their significance for providers and patients.
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
2 Clarke Drive
Cranbury, NJ 08512